Relmada Therapeutics (RLMD) Receives U.S. Patent Related to REL-1017

October 19, 2016 8:31 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Relmada Therapeutics, Inc. (OTC: RLMD) announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,468,611 for "d-Methadone for the Treatment of Psychiatric Symptoms." The patent contains claims that provide broad coverage for d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist, as a treatment for psychological and psychiatric disorders, comprising depression, anxiety, fatigue, and mood instability including pseudo-bulbar affect (PBA) for which there is currently only one U.S. Food and Drug Administration (FDA) approved treatment.

"The issuance of this key patent, which covers our lead product candidate REL-1017, further expands our intellectual property position," said Sergio Traversa, CEO of Relmada Therapeutics. "We look forward to initiating a Phase II proof-of-concept study with REL-1017 as a rapidly acting depression treatment as soon as feasible."

In May 2016, Relmada reported positive results from an in vivo study to determine whether REL-1017 elicits antidepressant-like effects within 24 hours after a single administration based on results of the forced swim test, a well-validated animal model to predict antidepressant effects. At all doses tested, REL-1017 significantly decreased immobility of rats compared to the vehicle, suggesting antidepressant-like activity. In addition, the effect of REL-1017 on immobility at the two highest doses tested was larger than the effect seen with ketamine, a noncompetitive NMDA receptor antagonist that has been thoroughly characterized in this model and has demonstrated rapid onset of activity in several clinical studies targeting treatment of depression, but has also been shown in multiple studies to present a high risk of toxicity.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation

Add Your Comment